H. Dar

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

D. Kalaitzidis, J. Terrett, D. R. Henderson, 2018, Blood.

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

N. Agarwal, M. Hurwitz, B. Tran, 2022, Regular and Young Investigator Award Abstracts.